Topic 8.14 · Patient edition

Oncology

Written for patients and families: plain language, same evidence posture. Literature reviewed 2026-09-13.

Plain-language overview

Oncology is the field of cancer care. Cell-based treatment already has an established role in some cancers, especially through hematopoietic stem-cell transplantation (HSCT). Other uses of cells and extracellular vesicles (EVs) are still being studied. These include repairing tissue damaged by cancer treatment, measuring cancer-related markers, and carrying drugs or genetic instructions to a tumor. These approaches are not interchangeable. A result with one product or cancer cannot be applied automatically to another. [1,2,15]

For treatment-related tissue injury, researchers are studying whether cell products can reduce symptoms or help normal tissue recover. In one randomized controlled trial of 120 head and neck cancer survivors, cells made from donor fat tissue were injected into damaged salivary glands. At twelve months, dry-mouth symptoms improved more with the cells than with placebo. However, measured saliva flow improved by the same small amount in both groups. Several other symptom measures also did not differ. The study therefore had a favorable symptom result and a null result for the main physical measurement. [3]

For bone-marrow support, the evidence is much more established. High-dose chemotherapy or radiation can severely damage marrow. HSCT can restore blood formation. A transplant using a patient's own cells mainly provides hematopoietic rescue. A donor transplant can also create a graft-versus-tumor effect, in which donor immune cells attack remaining cancer cells. These benefits come with serious transplant-specific risks. [1,2]

The tumor microenvironment includes cancer cells and the immune, blood-vessel, supporting, and signaling systems around them. Laboratory studies show that stromal cells can sometimes support tumor growth and sometimes inhibit it. The result depends on the cell product, tumor, dose, route, and model. This makes possible tumor-promoting effects important to test, but it does not show that every stromal-cell product promotes cancer in patients. [5-7]

EVs can carry proteins and genetic material released by cells. Cancer-related EVs in blood or saliva may become useful biomarkers. Reviews in ovarian cancer and other cancers found promising diagnostic signals, but collection and testing methods varied. EVs can also be engineered to deliver treatment. A small Phase I pancreatic-cancer study found early feasibility, target engagement, and no dose-limiting toxicity, but it did not prove that the treatment extends life or controls cancer better than standard care. [8-12]

Regulatory status depends on the exact product and use. The United States has approved specific cell products for specific indications. FDA's current approved-product list includes no exosome product. Approval of one cell product does not establish safety or effectiveness for another product or another cancer. [2,4,13-15]

Treatment-related tissue injury

Cancer treatment can damage normal tissues, including marrow, salivary glands, the mouth and digestive tract, skin, lung, heart, and nerves. Researchers hope some cell products may reduce inflammation, support repair, or improve symptoms. The exact injury, product, route, timing, and goal must be stated. A product used to treat an injury caused by cancer therapy is not necessarily an anticancer treatment. [3,4]

The randomized salivary-gland study used donor mesenchymal stromal cells (MSCs). At twelve months, patient-reported dry mouth improved more with MSCs than with placebo. Objective saliva flow—the study's main physical outcome—did not differ. Sticky saliva, swallowing, and another dry-mouth measure also did not differ significantly. The treatment was reported as safe, with a temporary immune response. These findings support further study for symptoms, while they do not show better restoration of saliva production. [3]

A separate MSC product, remestemcel-L-rknd, is FDA approved for children two months and older with steroid-refractory acute graft-versus-host disease (GVHD). This is a serious immune complication after a donor transplant. That approval does not apply to radiation injury, cancer treatment, or other MSC products. [4]

Figure 1 placeholder — Distinct oncology roles for cells and extracellular vesicles

Bone-marrow support

Hematopoietic stem cells make blood and immune cells. High-dose cancer therapy can destroy or greatly reduce marrow function. HSCT returns blood-forming cells so blood production can recover. In an autologous transplant, the cells come from the same patient. In an allogeneic transplant, they come from a donor. Donor immune cells may also attack cancer through a graft-versus-tumor effect, especially in blood cancers. [1]

In 2026, FDA approved HSPC and T cells-vldq for matched-donor transplantation in adults with certain blood cancers. In a randomized study of 187 adults, it improved survival without chronic GVHD compared with an unmanipulated donor graft. All 88 treated patients reached neutrophil recovery within 28 days. The product also has risks that include graft failure, GVHD, infusion reactions, infection transmission, and later cancers. This evidence applies to the defined product, transplant plan, and patient group. [2]

Tumor microenvironment

The tumor microenvironment includes malignant cells, immune cells, blood vessels, fibroblasts and other supporting cells, structural material, chemical signals, and EVs. Together, these can affect tumor growth, immune escape, invasion, spread, and response to treatment. The environment differs among cancers, patients, body sites, and stages of treatment. [5]

MSCs can move toward inflammatory and tumor-related signals. In laboratory models, they have shown both tumor-supporting and tumor-inhibiting effects. Tissue source, manufacturing, dose, route, activation state, tumor type, and follow-up can change the result. A mechanism found in one laboratory model does not define what every MSC product will do in every patient. [5]

Figure 2 placeholder — Tumor microenvironment and context-dependent stromal effects

Potential tumor-promoting effects

Possible tumor-promoting effects include helping an existing tumor survive, grow blood vessels, avoid immune attack, invade nearby tissue, or resist treatment. Other concerns include unintended cancer-related cargo, reinfusion of cancer cells in a patient's own graft, abnormal persistence or growth of administered cells, and product transformation. These are different risks and should be tested separately. [5,6,8,14]

A 2026 review combined eight laboratory studies of head and neck cancer cells exposed to MSCs. Some marker changes were consistent with a shift linked to greater cell movement and invasion. The studies differed, and they did not test tumor growth, recurrence, or survival in patients. The finding supports a possible mechanism that deserves study; it does not establish a uniform clinical effect. [6]

A separate safety review included 152 randomized trials and 9,228 participants who received MSCs for many conditions. Fever was the only common treatment-related adverse event that differed significantly from control groups. This is reassuring for the events and follow-up studied, but it cannot rule out rare, delayed, product-specific, or cancer-specific risks. [7]

EVs as biomarkers

A biomarker is a measurable sign of a biological process, disease, or response. Tumor-related EVs and their cargo can be measured in blood, saliva, or other fluids. A test using these materials is one form of liquid biopsy. Before clinical use, the test must show reliable measurement and accurate performance in the patients for whom it is intended. [8-10]

A 2026 review of EV microRNAs for ovarian-cancer detection included 27 studies and pooled 16 cohorts. Pooled sensitivity was 0.82, pooled specificity was 0.81, and the summary area under the curve was 0.88. These results are promising, but methods and study groups varied. A review of salivary EV markers for cancers outside the head and neck also found promising but uneven early evidence. Neither review establishes a ready-to-use screening test. [9,10]

Engineered EV drug delivery

An engineered extracellular vesicle is modified to carry or direct a chosen treatment. Researchers hope EVs may protect their cargo, reach selected tissues, and enter cells. Manufacturing must control source cells, vesicle identity, purity, potency, cargo amount, unwanted materials, sterility, dose, and storage. [8,11]

In a first-in-human Phase I study, engineered exosomes carried small interfering RNA (siRNA) aimed at the KRAS G12D cancer mutation in heavily pretreated people with metastatic pancreatic cancer. No dose-limiting toxicity occurred, and the highest tolerated dose was not reached. Investigators found target engagement, more CD8-positive immune cells within tumors, and stable disease in some participants. This is an early favorable feasibility and tolerability signal. Because the study was small, nonrandomized, and single-arm, it did not establish better tumor response, longer control, or longer survival than another treatment. [11,12]

Figure 3 placeholder — EV biomarker and engineered-delivery translation pathway

Regulatory status

Regulatory status depends on the exact product, disease, route, country, and date. In the United States, defined hematopoietic, immune-cell, and MSC products are approved for specified uses. FDA states that exosome products intended to treat disease generally require approval, and its current approved-product list includes no exosome product. A clinical trial listing does not mean that a product is approved or proven effective. [2,4,12-15]

Known and theoretical risks

Risks differ by product and treatment. They may include infusion or injection reactions, fever, infection, immune effects, bleeding or clots, organ injury, graft failure, GVHD, abnormal tissue growth, return or spread of cancer, a second cancer, unwanted genetic effects, or delivery to the wrong tissue. Transplantation may also require intensive chemotherapy. Short-term tolerability does not answer every question about rare or delayed harm. [1-8,11-14]

Standard-care alternatives

Standard care depends on the cancer and may include surgery, radiation therapy, chemotherapy, targeted treatment, immunotherapy, hormone treatment, established HSCT, symptom treatment, rehabilitation, and survivorship care. A study of tissue repair, a biomarker test, or EV delivery should be compared with the current standard for that exact problem. Investigational care should not replace effective standard care without a clear clinical reason. [1-4,16]

Questions to ask

What is the exact cell or EV product, and what is it intended to do?
Is the goal to treat cancer, restore marrow, repair treatment injury, measure a biomarker, or deliver a drug?
What human evidence used the same product, cancer, dose, route, and outcome?
Which results were favorable, which were null, and which outcomes important to patients remain uncertain?
Is this product FDA approved for this exact use, or is it being studied?
What short-term, delayed, transplant-related, and tumor-related risks will be monitored?
What standard treatment or supportive care would I receive outside the study?
How long is follow-up, and how will tumor response, recurrence, symptoms, and quality of life be measured?
Who makes the product, what release tests are used, and who pays for treatment and follow-up?

Bottom-line evidence statement

Cell-based treatment in oncology includes both established care and early research. HSCT is established for defined cancers and transplant settings. An MSC trial for radiation-related dry mouth found better symptoms but no advantage in measured saliva flow. Laboratory work identifies possible tumor-promoting and tumor-inhibiting stromal effects, without showing one uniform result in patients. EV biomarker reviews report promising accuracy signals, while engineered EV delivery has reached early human testing with favorable feasibility findings but no comparative proof of clinical benefit. The conclusion depends on the exact product, purpose, cancer, outcome, and follow-up. [1-15]

Evidence summary

Condition / product	Study design	Main result	Safety	Main limit
Radiation dry mouth / donor adipose MSC	Randomized Phase II; 120 enrolled; 117 at 12 months	Symptoms favored MSCs; measured saliva-flow outcome was null	Reported safe; temporary immune response	Single center; mixed outcome-specific result [3]
Pediatric steroid-refractory acute GVHD / remestemcel-L	Approved product for a defined use	Clinical benefit supports labeled transplant-complication use	Infusion and allergy precautions	Not evidence for cancer control or other MSC uses [4]
Matched-donor HSCT / HSPC and T cells-vldq	Randomized; 187 adults	Chronic-GVHD-free survival favored product; all treated patients had neutrophil recovery by day 28	Serious transplant- and product-specific risks	Defined blood cancers and transplant plan [2]
Head and neck cancer models / MSC exposure	Review of 8 laboratory studies	Some marker changes fit a possible tumor-supporting mechanism	Patient safety not tested	Laboratory evidence only [6]
Ovarian-cancer EV microRNAs	Systematic review; 27 studies; 16 pooled cohorts	Sensitivity 0.82; specificity 0.81; summary AUC 0.88	Diagnostic sampling, not treatment exposure	Methods varied; prospective validation needed [9]
KRAS G12D pancreatic cancer / engineered EV-siRNA	First-in-human, single-arm Phase I	No dose-limiting toxicity; target engagement; stable disease in some	Early tolerability favorable	Small and nonrandomized; comparative benefit unproven [11,12]

Public Evidence Appendix

Download the Public Evidence Appendix (PDF, 7 KB)

Methods and disclosure

Structured Educational Evidence Review per Dr. Mack Sullivan's Master Prompt v1.9 Revision 3E. Topics are literature-reviewed, evidence-graded, and finalised only after explicit author approval.

This library is educational and non-promotional. It does not recommend any specific product, clinic, or procedure, and no patient testimonials or outcome claims are published here.